Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3360321 | 0.92 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL2587945 | 0.91 | TLR7 (0.75) | TLR7TLR8 | |
| SCHEMBL1501487 | 0.90 | TLR7 (0.74) | TLR7TLR8 | |
| SCHEMBL1847376 | 0.87 | TLR7 (0.92) | TLR7TLR8 | |
| SCHEMBL1850014 | 0.87 | TLR7 (0.90) | TLR7TLR8 | |
| SCHEMBL2579983 | 0.86 | TLR7 (0.73) | TLR7TLR8 | |
| SCHEMBL567027 | 0.86 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL567197 | 0.86 | TLR7 (0.96) | TLR7TLR8 | |
| SCHEMBL1846454 | 0.86 | TLR7 (0.88) | TLR7TLR8 | |
| SCHEMBL1843707 | 0.86 | TLR7 (0.89) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138172-B2 | 8-oxoadenine derivatives acting as modulators of TLR7 | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-20100240623-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | ASTRAZENECA AB (SE) | 2010-09-23 | — | — | US | disclosed |
| EP-2041135-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | Astra Zeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090082332-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | ABBOT PHILIP | 2009-03-26 | — | — | US | disclosed |
| EP-1928877-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | Astra Zeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008004948-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007034173-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082332-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | ADORA3, ADORA1, P2RX1 | TLR7 271/4885TLR8 1382/4885 |
| US-20100240623-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | TLR7, TLR8, TLR9 | TLR7 1/4885TLR8 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.